

## Drug Monograph

Drug/Drug     **Acetaminophen, Caffeine and Dihydrocodeine Bitartrate**  
Class:         **tablets/ Short Acting Combination Opioids**  
Prepared for: MO HealthNet  
Prepared by: Conduent-Heritage

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Acetaminophen, caffeine and dihydrocodeine is available as a tablet containing 325 mg APAP, 30 mg caffeine, and 16 mg dihydrocodeine bitartrate per tablet.

**Manufacturer:** Larken Laboratories, Inc., Canton, MS 39046

**Indications:** Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain.

**Costs:** \$10.63 per tablet of Acetaminophen, caffeine, and dihydrocodeine. Wholesale Acquisition Cost

**Summary of Findings:** The Division recommends to continue Prior Authorization.

**Status Recommendation:**  Prior Authorization (PA) Required      Open Access  
 Fiscal Edit    Clinical Edit

**Type of PA Criteria:**  Increased Risk of ADE                                      Under Solicitation  
 Appropriate Indications    Non Preferred

Prepared By: Luke Boehmer Pharm.D.  
Date: August 17, 2017